These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 8957266

  • 1. Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains.
    Helmeste DM, Tang SW, Bunney WE, Potkin SG, Jones EG.
    Eur J Pharmacol; 1996 Oct 31; 314(3):R3-5. PubMed ID: 8957266
    [Abstract] [Full Text] [Related]

  • 2. Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.
    Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W, Potkin S, Jones EG.
    Brain Res; 1997 Aug 08; 765(1):7-12. PubMed ID: 9310388
    [Abstract] [Full Text] [Related]

  • 3. Brain sigma receptors labelled by [3H]nemonapride.
    Helmeste D, Tang SW, Fang H, Li M.
    Eur J Pharmacol; 1996 Apr 22; 301(1-3):R1-3. PubMed ID: 8773467
    [Abstract] [Full Text] [Related]

  • 4. Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride.
    Seeman P, Guan HC, Van Tol HH.
    Eur J Pharmacol; 1995 Nov 14; 286(2):R3-5. PubMed ID: 8605946
    [Abstract] [Full Text] [Related]

  • 5. Multiple [3H]-nemonapride binding sites in calf brain.
    Helmeste DM, Tang SW, Li M, Fang H.
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul 14; 356(1):17-21. PubMed ID: 9228185
    [Abstract] [Full Text] [Related]

  • 6. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients.
    Knable MB, Hyde TM, Herman MM, Carter JM, Bigelow L, Kleinman JE.
    Biol Psychiatry; 1994 Dec 15; 36(12):827-35. PubMed ID: 7893846
    [Abstract] [Full Text] [Related]

  • 7. In vivo binding of [11C]nemonapride to sigma receptors in the cortex and cerebellum.
    Ishiwata K, Senda M.
    Nucl Med Biol; 1999 Aug 15; 26(6):627-31. PubMed ID: 10587100
    [Abstract] [Full Text] [Related]

  • 8. The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia.
    Marzella PL, Hill C, Keks N, Singh B, Copolov D.
    Biol Psychiatry; 1997 Oct 15; 42(8):648-54. PubMed ID: 9325557
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Are striatal dopamine D4 receptors increased in schizophrenia?
    Reynolds GP, Mason SL.
    J Neurochem; 1994 Oct 15; 63(4):1576-7. PubMed ID: 7931313
    [Abstract] [Full Text] [Related]

  • 11. Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex.
    Noda-Saita K, Matsumoto M, Hidaka K, Hatanaka K, Ohmori J, Okada M, Yamaguchi T.
    Biochem Biophys Res Commun; 1999 Feb 16; 255(2):367-70. PubMed ID: 10049714
    [Abstract] [Full Text] [Related]

  • 12. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia.
    Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE.
    J Neurosci; 1995 Mar 16; 15(3 Pt 2):2186-91. PubMed ID: 7891160
    [Abstract] [Full Text] [Related]

  • 13. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression.
    Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY.
    Brain Res; 1995 May 29; 681(1-2):109-16. PubMed ID: 7552267
    [Abstract] [Full Text] [Related]

  • 14. Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride.
    Seeman P, Van Tol HH.
    J Neurochem; 1995 Mar 29; 64(3):1413-5. PubMed ID: 7861175
    [Abstract] [Full Text] [Related]

  • 15. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia.
    Reynolds GP, Mason SL.
    Eur J Pharmacol; 1995 Aug 04; 281(2):R5-6. PubMed ID: 7589196
    [Abstract] [Full Text] [Related]

  • 16. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
    Seeman P, Guan HC, Van Tol HH, Niznik HB.
    Synapse; 1993 Aug 04; 14(4):247-53. PubMed ID: 8248849
    [Abstract] [Full Text] [Related]

  • 17. Dopamine D2-like sites in schizophrenia, but not in Alzheimer's, Huntington's, or control brains, for [3H]benzquinoline.
    Seeman P, Guan HC, Nobrega J, Jiwa D, Markstein R, Balk JH, Picetti R, Borrelli E, Van Tol HH.
    Synapse; 1997 Feb 04; 25(2):137-46. PubMed ID: 9021894
    [Abstract] [Full Text] [Related]

  • 18. Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex.
    Assié MB, Consul-Denjean N, Koek W, Newman-Tancredi A.
    Pharmacology; 2005 Oct 04; 75(2):63-8. PubMed ID: 16020947
    [Abstract] [Full Text] [Related]

  • 19. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects.
    Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, Tamminga CA.
    Neuroreport; 1996 Aug 12; 7(12):1945-8. PubMed ID: 8905699
    [Abstract] [Full Text] [Related]

  • 20. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
    Florijn WJ, Tarazi FI, Creese I.
    J Pharmacol Exp Ther; 1997 Feb 12; 280(2):561-9. PubMed ID: 9023264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.